Last $11.59 USD
Change Today +1.04 / 9.82%
Volume 1.1M
NKTR On Other Exchanges
As of 12:59 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (NKTR) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $15.34
52 Week Low
11/7/13 - $8.87
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEKTAR THERAPEUTICS (NKTR)

nektar therapeutics (NKTR) Related Businessweek News

No Related Businessweek News Found

nektar therapeutics (NKTR) Details

Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company’s drug candidates in clinical development stage comprise naloxegol, an opioid antagonist, which has completed Phase III clinical trial for treating opioid-induced constipation; BAY41-6551 that is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181, which has completed Phase II clinical trial for chronic pain; and NKTR-171 that is in Phase I clinical trial to treat neuropathic pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase III clinical trial for metastatic breast cancer and in Phase II clinical trial for second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that has completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 to treat chronic pain; NKTR-192 to treat acute pain; and NKTR-214, a cytokine immunostimulatory therapy to treat oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551, which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB to develop and commercialize naloxegol and naloxegol fixed-dose combination program. Further, it has license, manufacturing, and supply agreements with Amgen Inc.; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche), Regado Biosciences, Inc.; and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

445 Employees
Last Reported Date: 02/27/14
Founded in 1990

nektar therapeutics (NKTR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $831.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $524.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $504.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $459.7K
Compensation as of Fiscal Year 2013.

nektar therapeutics (NKTR) Key Developments

Nektar Therapeutics to Report Q2, 2014 Results on Jul 31, 2014

Nektar Therapeutics announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

Nektar Therapeutics, Q2 2014 Earnings Call, Jul 31, 2014

Nektar Therapeutics, Q2 2014 Earnings Call, Jul 31, 2014

US FDA Advisory Committee Recommends No Cardiovascular Outcomes Trial for Peripherally-Acting Mu-Opioid Receptor Antagonist (PAMORA) Class Including Movantik

Nektar Therapeutics reported that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIK(TM) (naloxegol oxalate), an investigational treatment for opioid-induced constipation (OIC) for patients with chronic non-cancer pain. Following a clarification of the vote, the majority of the Committee suggested continued post-approval data collection for cardiovascular safety. The FDA convened a meeting of the AADPAC to review the class of peripherally acting opioid receptor antagonists on June 11-12, 2014. The meeting assessed the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in the class, for the proposed indication of OIC in patients taking opioids for chronic non-cancer pain. The FDA is not bound by the Advisory Committee's recommendation, but takes its advice into consideration when reviewing applications for investigational medicines. The Prescription Drug User Fee Act (PDUFA) date set by the FDA for MOVANTIK is September 16, 2014. MOVANTIK was designed using Nektar's proprietary oral, small molecule polymer conjugate technology. MOVANTIK is part of the exclusive worldwide licence agreement announced in September 2009 between AstraZeneca and Nektar. Opioids play an important role in chronic pain relief by binding mu-receptors in the brain, but they also bind mu-receptors in the bowel. That is why patients taking opioids for chronic pain can develop OIC. In fact, the incidence of OIC can be as high as 81% in patients taking opioids. There is a significant unmet need for safe, effective treatment options for patients with OIC. An estimated 235 million prescriptions for opioids are written in the US each year, of which 20% are for chronic pain. For patients taking prescription opioids for chronic pain, constipation is one of the most common side effects and one not adequately relieved by laxatives. In addition to the U.S., AstraZeneca has also submitted regulatory filings for MOVANTIK with health agencies in the European Union and Canada.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.64 USD +1.09

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $10.14 USD +0.19
Emergent Biosolutions Inc $21.77 USD -0.23
Ironwood Pharmaceuticals Inc $14.39 USD -0.4148
Sucampo Pharmaceuticals Inc $5.96 USD +0.06
Veloxis Pharmaceuticals A/S kr1.94 DKK -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation NKTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at